Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain scan method could spot Alzheimer's sooner

NCT ID NCT05579236

Knowledge-focused Sponsor: University Hospital Southampton NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new way to analyze MRI brain scans, called Cortical Disarray Measurement (CDM), to see if it can help diagnose Alzheimer's disease more accurately. Researchers will follow 400 people with mild memory or thinking problems over time, comparing CDM results with standard memory tests. The goal is to find a better tool for early diagnosis, which could lead to earlier treatment and planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a more accurate and earlier diagnosis of Alzheimer's disease using a simple MRI scan.
What could go wrong
This is an observational study, not a treatment trial. The new technique may not prove reliable enough for widespread use, and results may take years to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A total of 200 patient participants and 200 study companions will be recruited to the study. Patient participants will have a diagnosis of mild cognitive impairment or prodromal / mild Alzheimer's Disease. Participants with a global CDR score of 0.5 and 1 will be recruited in a minimum of a 2:1 ratio respectively in the study.

Ages

50 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

PATIENT PARTICIPANTS Inclusion Criteria: * Diagnosis of mild cognitive impairment (MCI) or prodromal Alzheimer's Disease (AD) as defined by National Institute on Ageing/Alzheimer's Association (NIA/AA) diagnostic criteria for MCI/prodromal AD, NOT including MCI unlikely due to AD; OR, Diagnosis of Alzheimer's disease as defined by NIA/AA criteria for probable AD * Clinical dementia rating (CDR) scale global score of very mild or mild (0.5 or 1) impairment * Ability to undergo and tolerate MRI scans, with no contraindications to MRI * Ability to tolerate blood draws * Ability to give informed consent to participate in the study Exclusion Criteria: * Do not meet the inclusion criteria * No study companion available * Individuals with a non-progressive learning disability * Pregnant or intending to become pregnant during the study COMPANION PARTICIPANTS Inclusion Criteria: * Aged over 18 years * Sufficient knowledge on study participant's condition to complete companion assessments of the patient, in the investigator's judgement * Able and willing to attend all clinical visits for completion of companion assessments or provide the relevant assessments remotely via phone or video call Exclusion Criteria: * A condition or reason, in the investigator's judgement, that would question the validity of the acquired companion reported data * Individuals who are not fluent in English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction dementia disease neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Dementia Mild cognitive impairment

Contacts and locations

Locations

  • Cardiff and Vale University Health Board

    Cardiff, United Kingdom

  • Dorset Healthcare University NHS Foundation Trust

    Bournemouth, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, Hampshire, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.